Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer?

The aim of this paper was to evaluate the activity and tolerability of oral vinorelbine in patients with advanced castration resistant prostate cancer (CRPC) who progressed after a minimum of three lines including: abiraterone acetate, docetaxel, cabazitaxel, and enzalutamide. Treatment consisted of...

Descripción completa

Detalles Bibliográficos
Autores principales: Roviello, Giandomenico, Corona, Silvia Paola, Conca, Raffaele, Petrioli, Roberto, Rosellini, Pietro, Bonetta, Alberto, Aieta, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616091/
https://www.ncbi.nlm.nih.gov/pubmed/31261590
http://dx.doi.org/10.1097/MD.0000000000016249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616091/
https://www.ncbi.nlm.nih.gov/pubmed/31261590
http://dx.doi.org/10.1097/MD.0000000000016249

Ejemplares similares